Ibogaine (12-methoxyibogamine) is a naturally occurring indole alkaloid derived primarily from the root bark of Tabernanthe iboga, a shrub native to Central Africa. Used ceremonially in Bwiti traditions for centuries, it is currently investigated for addiction interruption and depression. In the United States it remains a Schedule I controlled substance.

⚠️ Ibogaine carries serious cardiac risks and has caused fatalities. Medical supervision required. Do not self-administer.

How It Works

Ibogaine's therapeutic and psychoactive effects arise from simultaneous action across multiple neurotransmitter systems. No single mechanism fully accounts for its reported ability to interrupt substance dependence; current evidence points to a synergistic profile involving receptor pharmacology and downstream neuroplasticity signaling.

Kappa-Opioid Receptor Agonism

Ibogaine and its primary metabolite noribogaine act as agonists at kappa-opioid receptors (KORs). KOR activation is associated with dysphoria and dissociation during acute exposure but also modulates dopamine release in reward circuitry, a mechanism hypothesized to underlie its anti-craving effects. Noribogaine's relatively long half-life (28–49 hours) means KOR engagement persists well beyond the acute experience (Mash et al., 1995; Bhatt et al., 2024).

NMDA Receptor Antagonism

Ibogaine functions as a non-competitive antagonist at N-methyl-D-aspartate (NMDA) glutamate receptors, a property shared with ketamine. This antagonism is proposed to disrupt reconsolidation of drug-associated memories and to reduce the neuroadaptations underlying physical opioid dependence, potentially explaining rapid attenuation of withdrawal symptoms (Popik et al., 1995; Bhatt et al., 2024).

Serotonin Transporter Inhibition

Noribogaine is a potent serotonin reuptake inhibitor, with affinity for the serotonin transporter (SERT) comparable to selective serotonin reuptake inhibitors (SSRIs). This prolonged serotonergic activity is implicated in mood stabilization in the post-treatment period but also creates clinically significant interaction risks with serotonergic medications (Mash et al., 1995; Glue et al., 2016).

5-HT2A Receptor Agonism

Ibogaine exhibits partial agonism at 5-HT2A serotonin receptors, the primary target shared with classical psychedelics such as psilocybin and LSD. This activity is associated with the visionary or oneirogenic states reported during acute ibogaine experiences, and may contribute to psychological insights relevant to addiction recovery (Barsuglia et al., 2018).

GDNF and BDNF Neuroplasticity

Preclinical studies demonstrate that ibogaine significantly upregulates glial cell line-derived neurotrophic factor (GDNF) in the ventral tegmental area (VTA) and nucleus accumbens, brain regions central to addiction neurocircuitry. GDNF upregulation normalizes morphine-induced dopaminergic adaptations in animal models. Brain-derived neurotrophic factor (BDNF) increases have also been observed, supporting a neuroplasticity model of ibogaine's sustained effects (He et al., 2005; Marton et al., 2019).

Medical Research

Ibogaine research has accelerated substantially, moving from observational case series toward sponsored clinical trials. The table below summarizes key evidence across conditions currently under investigation.

Condition Phase Key Finding Citation
Opioid Use Disorder (OUD) Observational / Open-Label Single ibogaine treatment associated with significant reductions in opioid withdrawal severity and craving; 12-month follow-up showed sustained abstinence in a subset of participants in New Zealand cohort. Glue et al., J Psychopharmacol, 2016; Davis et al., 2017
Opioid Use Disorder (OUD) Phase 1 (NCT03380728) ATAI Life Sciences/DemeRx trial established dosing safety parameters and pharmacokinetic profile; noribogaine doses up to 120 mg appeared safe under cardiac monitoring. ClinicalTrials.gov NCT03380728; Glue et al., 2016
Methamphetamine Use Disorder Observational Retrospective case series reported reductions in methamphetamine use at 1-month follow-up following ibogaine treatment in Mexico-based clinic settings. Barsuglia et al., Am J Drug Alcohol Abuse, 2018
Alcohol Use Disorder Observational Reduced alcohol consumption and craving scores reported at 6-month follow-up in a prospective observational cohort; no randomized controlled data yet available. Brown & Alper, Am J Drug Alcohol Abuse, 2018
Treatment-Resistant Depression (TRD) Observational / Retrospective Participants reported significant reductions in depressive symptoms persisting weeks to months post-treatment; mechanistically attributed to SERT inhibition and neuroplasticity upregulation. Schenberg et al., J Psychoactive Drugs, 2014
Post-Traumatic Stress & TBI (Military Veterans) Prospective Open-Label (Stanford) Landmark 2024 Stanford study of 30 special operations veterans: single ibogaine treatment produced large-magnitude reductions in PTSD, anxiety, and depression scores sustained at 1-month follow-up; significant improvements in cognitive function. Cherian et al., Nature Medicine, 2024
Cocaine Use Disorder Preclinical / Early Observational Animal models show GDNF-mediated reduction in cocaine self-administration; human observational data limited but suggest reduced cocaine craving post-treatment. He et al., J Neurosci, 2005

Safety Profile

Cardiac Risks — QTc Prolongation

Ibogaine's most serious and well-documented risk is dose-dependent prolongation of the cardiac QTc interval, reflecting delayed ventricular repolarization. QTc prolongation elevates the risk of torsades de pointes, a potentially fatal ventricular arrhythmia. A 2012 systematic review identified at least 19 fatalities temporally associated with ibogaine administration; cardiac events were implicated in the majority of cases (Koenig & Hilber, 2015). A 2019 pharmacovigilance analysis found QTc increases of 30–100 ms during acute ibogaine treatment even in screened patients under medical supervision (Bhatt et al., 2024).

Ibogaine prolongs QTc through blockade of the hERG (IKr) cardiac potassium channel, the same mechanism responsible for QTc-prolonging effects of many antiarrhythmic drugs and antipsychotics. Noribogaine also blocks hERG independently, extending the window of cardiac risk.

Required Pre-Treatment Cardiac Screening

  • 12-lead electrocardiogram (ECG) — baseline QTc must generally be <450 ms (male) / <470 ms (female)
  • Echocardiogram to rule out structural cardiac disease
  • Electrolyte panel (potassium, magnesium, calcium) — hypokalemia and hypomagnesemia potentiate QTc prolongation
  • Liver function tests — ibogaine is hepatically metabolized via CYP2D6; impaired metabolism elevates plasma levels
  • Comprehensive medication review to identify QTc-prolonging co-medications
  • Continuous cardiac monitoring (telemetry) throughout treatment and for minimum 24 hours post-dosing

Drug Interactions

\ n
Drug Class Interaction Clinical Significance
SSRIs / SNRIs Additive serotonergic activity (ibogaine + noribogaine SERT inhibition); risk of serotonin syndrome Severe — SSRIs should generally be tapered and discontinued before ibogaine treatment; minimum washout periods depend on specific agent half-life
MAOIs Severe serotonin syndrome risk; combined inhibition of serotonin catabolism and reuptake Absolute contraindication; irreversible MAOIs require minimum 14-day washout
Opioids Risk of respiratory depression if opioids re-administered during noribogaine metabolic phase; ibogaine may precipitate opioid withdrawal via NMDA/opioid receptor mechanisms High — opioid timing must be carefully managed; do not administer opioids within established clearance windows post-ibogaine
QTc-Prolonging Agents (antiarrhythmics, antipsychotics, fluoroquinolones, methadone) Additive QTc prolongation; increased torsades de pointes risk Severe — contraindicated or requires specialist cardiac assessment and monitoring
Stimulants (amphetamines, cocaine) Increased cardiovascular strain; potential for hypertensive crisis; additive cardiac arrhythmia risk High — abstinence from stimulants required for minimum period before treatment
CYP2D6 Inhibitors (fluoxetine, bupropion, paroxetine) Inhibition of ibogaine metabolism → elevated plasma ibogaine and noribogaine levels → amplified QTc risk and toxicity High — CYP2D6 inhibitors require washout prior to ibogaine administration
Cannabis / THC Potential for additive psychoactive effects and mild QTc interaction; tachycardia may exacerbate cardiac risk Moderate — abstinence generally recommended in the peri-treatment period

Absolute Contraindications

  • Known cardiac arrhythmia or significant structural heart disease
  • Prolonged baseline QTc interval (>450 ms male / >470 ms female)
  • Current MAOI use (or within required washout period)
  • Severe hepatic impairment
  • Personal or family history of long QT syndrome
  • Pregnancy or breastfeeding
  • Current psychotic disorder or high-risk psychiatric instability
  • Severe hypertension uncontrolled at time of treatment

Other Adverse Effects

  • Neurological: Ataxia, tremor, nystagmus during acute phase (5–36 hours); cerebellar toxicity at high doses
  • Gastrointestinal: Nausea and vomiting common during acute phase
  • Psychological: Intense visionary states, anxiety, and psychological distress; risk of traumatic re-experiencing without adequate psychological preparation and support
  • Fatigue: Profound exhaustion following the acute experience, lasting days; total duration of acute phase typically 24–36 hours of wakefulness

Legal Status

Country Status Notes
United States Schedule I Controlled Substance Federally prohibited since 1970 under the Controlled Substances Act. No approved medical use. Research permitted under DEA Schedule I researcher license. Several states exploring regulatory reform. FDA Breakthrough Therapy Designation not yet granted as of current date.
Mexico Unscheduled / Legal Not listed as a controlled substance under Mexican law. Numerous licensed clinics operate legally, particularly in Tijuana and other border regions, serving primarily US and Canadian patients. Medical oversight standards vary by clinic.
Portugal Decriminalized (personal use) Under Portugal's landmark 2001 decriminalization law, personal possession of all drugs (including ibogaine) is a civil rather than criminal offense. Supply and trafficking remain criminal. No licensed ibogaine clinics operate under formal regulatory framework.
Netherlands Unscheduled / Tolerated Ibogaine is not listed on Dutch drug schedules. Several retreat centers operate legally, offering ibogaine treatment under medical supervision. Regulatory environment is permissive but lacks formal therapeutic licensing specific to ibogaine.
Canada Schedule III Controlled Substance Listed under Canada's Controlled Drugs and Substances Act. Health Canada has granted Special Access Program (SAP) exemptions allowing individual patients access to ibogaine treatment in specific circumstances, a pathway that has expanded in recent years.
New Zealand Class C Controlled Drug Ibogaine is controlled but clinical research has been conducted under approved protocols (Glue et al. studies). No licensed clinical treatment program currently exists.
South Africa Unscheduled / Legal Not scheduled under South African drug legislation. Licensed clinics operate legally, offering ibogaine-assisted treatment primarily for substance use disorders. Considered one of the more established legal treatment markets.
Costa Rica Unscheduled / Legal Ibogaine is not controlled under Costa Rican law. Several retreat and treatment centers operate legally, attracting international patients. Medical oversight requirements vary.

Frequently Asked Questions

Ibogaine is an indole alkaloid naturally found in highest concentrations in the root bark of Tabernanthe iboga, a shrub indigenous to the rainforests of Gabon, Cameroon, and neighboring Central African nations. The Bwiti people of Gabon have used iboga root bark in initiation and healing ceremonies for centuries. Ibogaine was first isolated in 1901 by Dybowski and Landrin and later synthesized. Smaller quantities of ibogaine-class alkaloids occur in related plant species including Voacanga africana and Tabernaemontana undulata. For research and clinical use, ibogaine hydrochloride (ibogaine HCl) is the most commonly employed purified form, while some traditional and retreat settings use total alkaloid extracts (TA) or the raw root bark.
The acute psychoactive phase of ibogaine following a full therapeutic dose (typically 10–25 mg/kg in clinical observational settings) generally lasts 18–36 hours, making it significantly longer than any other commonly studied psychedelic. The experience is typically divided into three phases: an acute visionary phase (approximately the first 4–8 hours), a reflective or evaluative phase (hours 8–20), and a residual stimulation phase in which sleep is difficult despite profound fatigue. The primary metabolite noribogaine has a half-life of 28–49 hours, meaning pharmacologically active compound remains in the body for several days post-treatment. Full neurological resolution, including restoration of normal sleep architecture, typically occurs over 2–7 days (Mash et al., 1995; Glue et al., 2016).
Clinical and observational evidence consistently reports dramatic attenuation — and in many cases near-complete suppression — of opioid withdrawal symptoms following a single ibogaine dose. A New Zealand open-label study by Glue et al. (2016) documented significant reductions in Clinical Opiate Withdrawal Scale (COWS) scores within hours of ibogaine administration. The proposed mechanism involves NMDA receptor antagonism disrupting the neuroadaptive processes underlying physical dependence, combined with kappa-opioid receptor activity and noribogaine's prolonged serotonergic effects. However, it is critical to distinguish withdrawal interruption from long-term sobriety: ibogaine does not guarantee sustained abstinence, and many patients benefit substantially from integration therapy, peer support, and continued care after ibogaine treatment. Randomized controlled trials are ongoing and needed to establish efficacy rigorously (ClinicalTrials.gov NCT03380728).
The most serious risk is cardiac arrhythmia, specifically QTc interval prolongation leading to torsades de pointes and potentially fatal ventricular fibrillation. Ibogaine and noribogaine both block the hERG cardiac potassium channel, and this risk is amplified by co-ingested QTc-prolonging substances, electrolyte imbalances, underlying heart disease, and CYP2D6 polymorphisms that slow metabolism. A systematic review identified at least 19 deaths temporally associated with ibogaine; cardiac causes were predominant (Koenig & Hilber, 2015). Additional risks include cerebellar ataxia and tremor (dose-dependent), profound psychological distress during the acute phase, serotonin syndrome when combined with serotonergic drugs, and risks associated with atypical metabolizer status. Rigorous pre-treatment cardiac screening, continuous ECG monitoring, and qualified medical oversight substantially reduce but do not eliminate these risks.
No. Ibogaine is a Schedule I controlled substance under the US Controlled Substances Act, a classification it has held since 1970. Schedule I denotes that the federal government currently considers it to have no accepted medical use and a high potential for abuse — a designation that researchers and advocates dispute but that has not been formally revisited through rescheduling petition. Possession, distribution, and manufacture are federal criminal offenses. Research is permitted under a DEA Schedule I researcher license and IND (Investigational New Drug) application from the FDA. State-level legislative activity has increased, with several states introducing bills to explore regulatory pathways or create research programs, but no state has successfully established a legal ibogaine treatment framework as of early 2026. American patients commonly travel to Mexico, the Netherlands, or other jurisdictions where treatment is legal.
The 2024 Stanford University study published in Nature Medicine (Cherian et al., 2024) enrolled 30 US special operations veterans with significant histories of traumatic brain injury (TBI), PTSD, and other trauma-related conditions. Participants received a single ibogaine treatment in a licensed clinic in Mexico under medical supervision. At one-month follow-up, the study reported statistically and clinically significant reductions in PTSD symptom severity (averaging approximately 88% reduction on the PCL-5), anxiety, and depression scores, as well as meaningful improvements in cognitive function measures. The findings were described as representing some of the largest effect sizes observed in psychedelic research to date. Limitations acknowledged by the authors include the absence of a control group, the small sample size, the select population (special operations veterans), and the one-month follow-up window. Longer-term follow-up and randomized controlled trials are needed to confirm and generalize these findings.
Ibogaine differs from other investigational psychedelics in several critical dimensions. Pharmacologically, it engages a far broader receptor profile — including kappa-opioid, NMDA, SERT, and 5-HT2A targets simultaneously — compared to psilocybin (primarily 5-HT2A) or MDMA (primarily SERT/NET/DAT release). The acute experience lasts 24–36 hours, versus 4–6 hours for psilocybin and 3–5 hours for MDMA. Ibogaine's cardiac risk profile is substantially higher than either comparator; psilocybin and MDMA carry no significant QTc-prolonging effects, though MDMA carries cardiovascular risks through different mechanisms (sympathomimetic activity). Ibogaine's oneirogenic (waking-dream) phenomenology is described as distinctly different from psilocybin's ego-dissolving or MDMA's empathogenic quality — often characterized as a confrontational autobiographical review. GDNF upregulation is unique to ibogaine among current clinical candidates. Regulatory status differs as well: psilocybin and MDMA have achieved FDA Breakthrough Therapy Designation; ibogaine has not (Mash et al., 1995; Carhart-Harris & Goodwin, 2017).
Noribogaine (10-hydroxyibogamine) is the primary active metabolite of ibogaine, formed through O-demethylation primarily by the liver enzyme CYP2D6. It is pharmacologically active in its own right and is widely considered to be responsible for much of ibogaine's sustained post-acute effects. Key properties of noribogaine include: potent serotonin transporter (SERT) inhibition (comparable to clinical SSRIs), kappa-opioid receptor agonism, and independent hERG channel blockade contributing to QTc prolongation risk. Its half-life of 28–49 hours is substantially longer than ibogaine's own half-life of approximately 4–7 hours, meaning noribogaine dominates the pharmacokinetic profile for most of the post-treatment period. CYP2D6 poor metabolizers — approximately 7–10% of European-ancestry populations — accumulate higher ibogaine levels and lower noribogaine levels, altering both the efficacy and safety profile. Noribogaine has also been investigated as a standalone therapeutic agent (DemeRx NBI-98854 program) to capture therapeutic effects with potentially improved cardiac safety (Mash et al., 1995; Glue et al., 2016; Bhatt et al., 2024).

Informational only. Not medical advice. Ibogaine is Schedule I in the US. Consult qualified professionals before considering treatment.